Abeona Therapeutics Inc. Options
ABEO options chain
Explore expirations, strikes, liquidity, live quotes and Greeks in the context of the same company overview.
Options Chain SnapshotA bounded snapshot of up to 200 active contracts in the displayed expiration and strike window. Close and open interest are reference fields, not live quotes.
Up to 200 active ABEO contracts expiring in the next 7–45 days, with strikes within ±25% of the current price.
| Expiration | Days to expiry | Shown contracts |
|---|---|---|
| 2026-11-20 | 14 | 4 |
| 2026-12-18 | 42 | 4 |
| Type | Strike | Expiry | Open interest | Close |
|---|---|---|---|---|
| Call | $3.00 | 2026-11-20 | — | — |
| Call | $4.00 | 2026-11-20 | 31 | $0.40 |
| Put | $3.00 | 2026-11-20 | — | — |
| Put | $4.00 | 2026-11-20 | 105 | $0.25 |
| Call | $3.00 | 2026-12-18 | 130 | $3.07 |
| Call | $4.00 | 2026-12-18 | 161 | $2.36 |
| Put | $3.00 | 2026-12-18 | — | — |
| Put | $4.00 | 2026-12-18 | 11 | $0.16 |
- Source
- US listed-options contracts feed
- Observed
- Cadence
- Five-minute cached contract snapshot
- Status
- fresh
Live Quotes & GreeksThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Options Ideas & Decision IntelligenceThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Asset BackgroundSource-supported background about this asset. The sources and review status are listed with the reference.
ABEO options refer to ABEONA THERAPEUTICS INC. as their underlying. Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
AI-selected reference, checked against source evidence · Evidence observed
Frequently Asked QuestionsSource-linked answers to common questions about this asset. Check the evidence observation date and whether the reference was reviewed by a person.
- What business does ABEONA THERAPEUTICS INC. operate?
- Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
- How do ABEO options relate to the underlying company?
- The published options record identifies ABEO as an underlying symbol. Options contracts reference that underlying; expiration, strike and option type define each separate contract.
What to WatchAI-assisted topics for further research about this asset. These are educational prompts, not trading signals or recommendations.
- Business activities described in the company reference
- Original company disclosures and industry classification